Showing results (351-360 of 374) with videos related to
Sort By:
Pageof 38
Journal of Pharmaceutical Analysis|July 11, 2026
Discovery and optimization of a novel non-nitrocatechol COMT inhibitor for modulating levodopa metabolismRong Zhu, Pu Wang, Sheng-Lan Qi, et al.European Journal of Clinical Pharmacology|August 17, 2013
Cytochrome P450 oxidoreductase genetic polymorphisms A503V and rs2868177 do not significantly affect warfarin stable dosage in Han-Chinese patients with mechanical heart valve replacementSheng-Lan Tan, Zhi Li, Wei Zhang, et al.Medcomm|June 30, 2025
Triplet Regimen of Metronomic Capecitabine Plus Antiangiogenic Drug and PD-1 Inhibitor as Later-Line Salvage Treatment for Patients With MSS/pMMR Metastatic Colorectal Cancer: A Retrospective StudyQiong Yang, Yuan-Yuan Huang, Kai-Cong Zhang, et al.American Journal of Cancer Research|June 6, 2015
Epigenetic modulation of insulin-like growth factor-II overexpression by hepatitis B virus X protein in hepatocellular carcinomaXu You Liu, Shao Hui Tang, Sheng Lan Wu, et al.Journal of Molecular and Cellular Cardiology|June 6, 2024
Role of 8-hydroxyguanine DNA glycosidase 1 deficiency in exacerbating diabetic cardiomyopathy through the regulation of insulin resistanceXiao-Min Li, Zi-Jun Wu, Jun-Yu Fan, et al.Journal of Translational Medicine|May 1, 2026
Cargo molecules in plasma neural-derived extracellular vesicles reveal pathological signatures of primary open-angle glaucomaXiang-Yuan Song, Jing Zhang, Sheng-Lan Xu, et al.Journal of Cancer|January 10, 2022
Mitochondrial Dynamics Mediated by DRP1 and MFN2 Contributes to Cisplatin Chemoresistance in Human Ovarian Cancer SKOV3 cellsGuang-Ping Zou, Chun-Xia Yu, Sheng-Lan Shi, et al.Journal of Clinical Pharmacology|September 5, 2014
Effect of CYP2C9-VKORC1 interaction on warfarin stable dosage and its predictive algorithmXi Li, Rong Liu, Han Yan, et al.European Journal of Medicinal Chemistry|October 17, 2025
Discovery of anti-tumor targets based on photo-affinity labelingSi-Shuang Kang, Jin-Xia Lan, Hao Huang, et al.Acta Pharmacologica Sinica|March 26, 2021
CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemiaZe-An Zhao, Yu Jiang, Yan-Yu Chen, et al.Pageof 38